Alpha2delta ligands for fibromyalgia and other disorders

Details Alpha2delta ligands for fibromyalgia and other disorders Alpha2delta ligands for fibromyalgia and other disorders

2007-01-16

2007-01-16

Carr, Deborah D. (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Fatty compounds having an acid moiety which contains the...

C554S103000, C514S557000, C514S558000, C514S559000, C514S560000, C514S574000, C514S741000, C562S433000, C562S512000, C562S553000, C564S453000, C564S454000, C564S463000, C564S503000, C564S509000

Reexamination Certificate

active

10734917

ABSTRACT:
This invention relates to a method of treating a disorder selected from OCD, agoraphobia, agoraphobia without history of panic disorder, specific phobia, social phobia, PTSD, restless legs syndrome, premenstrual dysphoric disorder, hot flashes, and fibromyalgia by administering a compound of the formula 1or a pharmaceutically acceptable salt thereof, wherein:R1is hydrogen, straight or branched alkyl of from 1 to 6 carbon atoms or phenyl; andR2is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The invention also relates to a method of treating the above disorders by administering the compound (3S,5R)-3-Aminomethyl-5-methyl-octanoic acid.

REFERENCES:
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4087544 (1978-05-01), Satzinger et al.
patent: 5670539 (1997-09-01), Richardson
patent: 5919823 (1999-07-01), Richardson
patent: 6001876 (1999-12-01), Singh
patent: 6117908 (2000-09-01), Andrews et al.
patent: 6127418 (2000-10-01), Bueno et al.
patent: 6248363 (2001-06-01), Patel et al.
patent: 6306910 (2001-10-01), Magnus et al.
patent: 6309663 (2001-10-01), Patel et al.
patent: 6310098 (2001-10-01), Guttuso, Jr.
patent: 6372792 (2002-04-01), Chouinard
patent: 2002/0035057 (2002-03-01), Richter et al.
patent: 2002/0037926 (2002-03-01), Lan
patent: 2002/0072538 (2002-06-01), Chenard et al.
patent: 2002/0099013 (2002-07-01), Piccariello et al.
patent: 2002/0099092 (2002-07-01), Blakemore et al.
patent: 2002/0165246 (2002-11-01), Holman
patent: 2003/0144214 (2003-07-01), Blakemore et al.
patent: 198 02 327 (1999-07-01), None
patent: 0641330 (2001-10-01), None
patent: WO 98/17627 (1998-04-01), None
patent: WO 99/21824 (1999-05-01), None
patent: WO 00/76958 (2000-12-01), None
patent: WO 01/13904 (2001-03-01), None
patent: WO 01/28978 (2001-04-01), None
patent: WO 01/45714 (2001-06-01), None
patent: WO 01/90052 (2001-11-01), None
patent: WO 02/34237 (2002-05-01), None
patent: WO 03/061656 (2003-07-01), None
M. V. Ameringen et al., “Drugs in development for social anxiety disorder:more to social anxiety than meets the SSRI” Expert Opinion on Investigational Drugs, Ashley Pub. Ltd., London, GB 2000:2215-2231; vol. 9, No. 10.
A. Barkhuizen, “Rational and targeted pharmacologic treatment of fibromyalgia” Rheum Dis Clin N Am 2002;28:261-290.
R. M. Bennett, “The rational management of fibromyalgia patients” Rheum Dis Clin N Am 2002; 28: 181-199.
D. Buskila, “Fibromyalgia, chronic fatigue syndrome and myofacial pain syndrome” Current opinions in Rheumatology 2001;13:117-127.
B. L. Ehrenberg, et al., “Open-Label Trial of Gabapentin for Periodic Limb Movement Disorder of Sleep”, 1997, pp. A278-A279, vol. 48.
E. K. Guymer, et al., “An approach to managing fibromyalgia” Medicine Today 2002:58-59; vol. 3, No. 12.
L. J. Leventhal, “Management of fibromyalgia” Ann Intern Med 1999;131:850-8.
L. T. Meltzer, et al., “Pregabalin enhances non-rapid eye movement sleep and eeg slow-wave activity in rats” Society for neuro. abstracts 2001:2245 vol. 27, No. 2.
I. Selak, “Pregabalin (Pfizer)” Current opinion in investigational drugs, current drugs, Lond, GB 2001:828-834; vol. 2, No. 6.
F. Wolfe, et al., “The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee” Arthritis Rheum 1990; 33:160-72.
M. B. Yunus. “A comprehensive medical evaluation of patients with fibromyalgia syndrome” Rheum Dis N Am 2002; 28:201-217.
D. Garcia-Borreguero et al., “Treatment of restless legs syndrome with gabapentin—A double-blind, cross-over study” Neurology 2002;59:1573-1579.
Nelson, Heidi D., et al., Journal of American Medical Association, “Nonhormonal Therapies for Menopausal Hot Flashes Systematic Review and Meta-analysis”, May 3, 2006, vol. 295, No. 17, pp. 2057-2071.

Affiliated with

Also associated with

Rating

Alpha2delta ligands for fibromyalgia and other disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alpha2delta ligands for fibromyalgia and other disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alpha2delta ligands for fibromyalgia and other disorders will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3728396